On September 2, 2025, Jim O’Neill, a former biotech investor, was named acting CDC director amid turmoil following the ouster of Susan Monarez and resignations of three senior leaders. O’Neill faces a pivotal September vaccine advisory meeting that could reshape childhood immunization policies.
Leadership Transition
O’Neill, also HHS deputy secretary, assumed the CDC role after Monarez’s dismissal for resisting Health Secretary Robert F. Kennedy Jr.’s vaccine agenda. The resignations of the chief medical officer, vaccine safety head, and respiratory infections director highlight internal dissent over politicized science.
Vaccine Advisory Meeting
The CDC’s Advisory Committee on Immunization Practices (ACIP), now composed of Kennedy’s appointees, will meet in September to review the newborn hepatitis B dose, infant RSV protection, COVID vaccines for healthy youth, and the measles-mumps-rubella-varicella (MMRV) shot. This unprecedented review raises concerns about weakened recommendations.
Potential Impacts
Changes to vaccine policies could limit Medicaid, CHIP, and Vaccines for Children program coverage, creating access barriers for families. Experts warn this risks outbreaks of preventable diseases like measles, especially with flu, RSV, and COVID converging this fall.
O’Neill’s Background and Challenges
Lacking medical or scientific training, O’Neill’s libertarian views and past support for unproven COVID treatments like ivermectin raise doubts about his leadership. His 2014 FDA proposal to prioritize drug safety over efficacy was widely criticized. He must now restore trust through transparent, evidence-based processes.
Future Outlook
The September meeting is O’Neill’s first test. Transparent reviews and expert-driven decisions could stabilize CDC morale and credibility. Failure to do so may trigger further resignations, leaving states and families without clear guidance during a critical public health season.
